{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,22]],"date-time":"2026-10-22T17:56:14Z","timestamp":1792691774501,"version":"4.5.0"},"reference-count":23,"publisher":"Springer Science and Business Media LLC","issue":"8","license":[{"start":{"date-parts":[[2026,6,5]],"date-time":"2026-06-05T00:00:00Z","timestamp":1780617600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"},{"start":{"date-parts":[[2026,6,5]],"date-time":"2026-06-05T00:00:00Z","timestamp":1780617600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Drugs"],"published-print":{"date-parts":[[2026,8]]},"DOI":"10.1007\/s40265-026-02340-y","type":"journal-article","created":{"date-parts":[[2026,6,5]],"date-time":"2026-06-05T01:37:16Z","timestamp":1780623436000},"page":"1401-1407","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":2,"title":["Icotrokinra: First Approval"],"prefix":"10.1007","volume":"86","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-0121-7645","authenticated-orcid":false,"given":"Susan J.","family":"Keam","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,6,5]]},"reference":[{"issue":"7","key":"2340_CR1","doi-asserted-by":"publisher","first-page":"3158","DOI":"10.1007\/s12325-025-03213-8","volume":"42","author":"L Stein Gold","year":"2025","unstructured":"Stein Gold L, Eyerich K, Merola JF, et al. Oral peptide therapeutics as an emerging treatment modality in immune-mediated inflammatory diseases: a narrative review. Adv Ther. 2025;42(7):3158\u201372.","journal-title":"Adv Ther"},{"issue":"17515","key":"2340_CR2","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1038\/s41598-024-67371-5","volume":"14","author":"AM Fourie","year":"2024","unstructured":"Fourie AM, Cheng X, Chang L, et al. JNJ-77242113, a highly potent, selective peptide targeting the IL-23 receptor, provides robust IL-23 pathway inhibition upon oral dosing in rats and humans. Sci Rep. 2024;14(17515):1\u201312.","journal-title":"Sci Rep"},{"key":"2340_CR3","doi-asserted-by":"publisher","DOI":"10.1007\/s40257-026-01019-0","author":"C Ferreira","year":"2026","unstructured":"Ferreira C, Torres T. Icotrokinra: an oral interleukin-23 receptor antagonist peptide for the treatment of psoriasis. Am J Clin Dermatol. 2026. https:\/\/doi.org\/10.1007\/s40257-026-01019-0.","journal-title":"Am J Clin Dermatol"},{"key":"2340_CR4","unstructured":"Johnson & Johnson. Icotrokinra results show potential to set a new standard of treatment in plaque psoriasis [media release]. 8 Mar 2025. http:\/\/www.jnj.com."},{"key":"2340_CR5","unstructured":"Janssen Biotech. Icotrokinra: US prescribing information 2026. https:\/\/www.jnjlabels.com\/package-insert\/product-monograph\/prescribing-information\/ICOTYDE-pi.pdf. Accessed 15 Apr 2026"},{"key":"2340_CR6","unstructured":"Johnson & Johnson. Johnson & Johnson seeks first icotrokinra U.S. FDA approval aiming to revolutionize treatment paradigm for adults and adolescents with plaque psoriasis [media release]. 21 Jul 2025. http:\/\/www.jnj.com."},{"key":"2340_CR7","unstructured":"Johnson & Johnson. FDA approval of ICOTYDE\u2122 (icotrokinra) ushers in new era for first-line systemic treatment of plaque psoriasis with a targeted oral peptide [media release]. 18 Mar 2026. https:\/\/www.jnj.com\/."},{"key":"2340_CR8","unstructured":"Johnson & Johnson. Johnson & Johnson seeks first European Medicines Agency approval for icotrokinra aiming to transform the plaque psoriasis treatment paradigm [media release]. 11 Sep 2025. https:\/\/www.jnj.com\/."},{"key":"2340_CR9","unstructured":"Health Canada. Drug and health product submissions under review (SUR): new drug submissions under review. 2026. https:\/\/www.canada.ca\/. Accessed 10 Apr 2026."},{"key":"2340_CR10","unstructured":"Protagonist Therapeutics. Protagonist Therapeutics announces advancement of oral IL-23 receptor antagonists program in collaboration with Janssen [media release]. 29 Oct 2020. https:\/\/www.protagonist-inc.com\/."},{"key":"2340_CR11","unstructured":"Protagonist Therapeutics. Protagonist Therapeutics announces closing of Janssen license and collaboration agreement for PTG-200 and receipt of $50 million payment [media release]. 24 Aug 2017. https:\/\/www.protagonist-inc.com\/."},{"key":"2340_CR12","unstructured":"Protagonist Therapeutics. Protagonist Therapeutics announces amendment of agreement with Janssen Biotech for the continued development and commercialization of IL-23 antagonists [media release]. 28 Jul 2021. https:\/\/www.protagonist-inc.com\/."},{"issue":"Suppl 1","key":"2340_CR13","doi-asserted-by":"publisher","DOI":"10.1093\/ecco-jcc\/jjad212.0756","volume":"18","author":"A de Leon-Tabaldo","year":"2024","unstructured":"de Leon-Tabaldo A, Strawn D, Chang L, et al. JNJ-77242113, an oral peptide selectively targeting the IL-23 receptor, demonstrates pharmacodynamic activity in rat and human colon tissue explants following oral dosing [abstract no. P626]. J Crohns Colitis. 2024;18(Suppl 1):i1193.","journal-title":"J Crohns Colitis"},{"issue":"Suppl 9","key":"2340_CR14","first-page":"1067","volume":"77","author":"J Angsana","year":"2025","unstructured":"Angsana J, Polak M, Nischal S, et al. Early systemic and skin pharmacodynamic effects of icotrokinra in participants with moderate-to-severe plaque psoriasis: results through week 24 of the phase 3, ICONIC-LEAD Study [abstract no 0558 plus poster]. Arthritis Rheumatol. 2025;77(Suppl 9):1067\u20138.","journal-title":"Arthritis Rheumatol"},{"issue":"24","key":"2340_CR15","doi-asserted-by":"publisher","DOI":"10.1172\/jci.insight.193563","volume":"10","author":"D Strawn","year":"2025","unstructured":"Strawn D, Krueger JG, Bissonnette R, et al. Icotrokinra induces early and sustained pharmacodynamic responses in phase IIb study of patients with moderate-to-severe psoriasis. JCI Insight. 2025;10(24):e193563.","journal-title":"JCI Insight"},{"issue":"Suppl 1","key":"2340_CR16","first-page":"i68","volume":"20","author":"E Louis","year":"2026","unstructured":"Louis E, Jairath, Siegmund B, et al. Icotrokinra, the first targeted oral peptide that selectively blocks the interleukin-23 receptor, reduces systemic and tissue inflammatory burden in ulcerative colitis: results from the ANTHEM-UC study [abstract no. OP29 plus presentation]. J Crohns Colitis. 2026;20(Suppl 1):i68\u20139.","journal-title":"J Crohns Colitis"},{"issue":"9","key":"2340_CR17","doi-asserted-by":"publisher","first-page":"2495","DOI":"10.1007\/s13555-025-01454-7","volume":"15","author":"B Knight","year":"2025","unstructured":"Knight B, Tammara B, Modi NB, et al. Translational pharmacokinetics of icotrokinra, a targeted oral peptide that selectively blocks interleukin-23 receptor and inhibits signaling. Dermatol Ther (Heidelb). 2025;15(9):2495\u2013520.","journal-title":"Dermatol Ther (Heidelb)."},{"issue":"10510","key":"2340_CR18","doi-asserted-by":"publisher","first-page":"1363","DOI":"10.1016\/S0140-6736(25)01576-4","volume":"406","author":"L Stein Gold","year":"2025","unstructured":"Stein Gold L, Armstrong AW, Bissonnette R, et al. Once-daily oral Icotrokinra versus placebo and once-daily oral Deucravacitinib in participants with moderate-to-severe plaque psoriasis (ICONIC-ADVANCE 1 & 2): two phase 3, randomised, placebo-controlled and active-comparator-controlled trials. Lancet. 2025;406(10510):1363\u201374.","journal-title":"Lancet"},{"issue":"18","key":"2340_CR19","doi-asserted-by":"publisher","first-page":"1784","DOI":"10.1056\/NEJMoa2504187","volume":"393","author":"R Bissonnette","year":"2025","unstructured":"Bissonnette R, Soung J, Hebert AA, et al. Oral Icotrokinra for plaque psoriasis in adults and adolescents. N Engl J Med. 2025;393(18):1784\u201395.","journal-title":"N Engl J Med"},{"key":"2340_CR20","doi-asserted-by":"publisher","DOI":"10.1056\/EVIDoa2500155","author":"M Gooderham","year":"2025","unstructured":"Gooderham M, Lain E, Bissonnette R, et al. Targeted oral peptide icotrokinra for psoriasis involving high-impact sites. NEJM Evid. 2025. https:\/\/doi.org\/10.1056\/EVIDoa2500155.","journal-title":"NEJM Evid."},{"issue":"6","key":"2340_CR21","doi-asserted-by":"publisher","first-page":"510","DOI":"10.1056\/NEJMoa2308713","volume":"390","author":"R Bissonnette","year":"2024","unstructured":"Bissonnette R, Pinter A, Ferris LK, et al. An oral interleukin-23-receptor antagonist peptide for plaque psoriasis. N Engl J Med. 2024;390(6):510\u201321.","journal-title":"N Engl J Med"},{"issue":"3","key":"2340_CR22","doi-asserted-by":"publisher","first-page":"495","DOI":"10.1016\/j.jaad.2024.10.076","volume":"92","author":"LK Ferris","year":"2025","unstructured":"Ferris LK, Bagel J, Huang YH, et al. FRONTIER-2: a phase 2b, long-term extension, dose-ranging study of oral JNJ-77242113 for the treatment of moderate-to-severe plaque psoriasis. J Am Acad Dermatol. 2025;92(3):495\u2013502.","journal-title":"J Am Acad Dermatol"},{"issue":"Suppl 8","key":"2340_CR23","first-page":"172","volume":"13","author":"MT Abreu","year":"2025","unstructured":"Abreu MT, Siegmund B, Surace L, et al. Icotrokinra, a targeted oral peptide that selectively blocks IL-23 receptor activation, in moderately to severely active ulcerative colitis: week 12 results from the phase 2b, randomized, double-blind, placebo-controlled, treat-through, dose-ranging ANTHEM-UC trial [abstract no. OP206 plus presentation]. United Eur Gastroenterol J. 2025;13(Suppl 8):172\u20133.","journal-title":"United Eur Gastroenterol J"}],"container-title":["Drugs"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40265-026-02340-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s40265-026-02340-y","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40265-026-02340-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,9,18]],"date-time":"2026-09-18T01:51:21Z","timestamp":1789696281000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s40265-026-02340-y"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,6,5]]},"references-count":23,"journal-issue":{"issue":"8","published-print":{"date-parts":[[2026,8]]}},"alternative-id":["2340"],"URL":"https:\/\/doi.org\/10.1007\/s40265-026-02340-y","relation":{},"ISSN":["0012-6667","1179-1950"],"issn-type":[{"value":"0012-6667","type":"print"},{"value":"1179-1950","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,6,5]]},"assertion":[{"value":"17 April 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"10 May 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"5 June 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"18 September 2026","order":5,"name":"change_date","label":"Change Date","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Update","order":6,"name":"change_type","label":"Change Type","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"This article was originally published under the subscription model but it is now published under an Open Access license.","order":7,"name":"change_details","label":"Change Details","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"During the peer review process the manufacturer of the agent under review was offered an opportunity to comment on the article. Changes resulting from any comments received were made by the authors on the basis of scientific completeness and accuracy. Susan J. Keam is a contracted employee of Adis International Ltd\/Springer Nature, and declares no relevant conflicts of interest. All authors contributed to this article and are responsible for its content.","order":1,"name":"Ethics","label":"Authorship and Conflict of interest","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable.","order":2,"name":"Ethics","label":"Ethics Approval, Consent to Participate, Consent to Publish, Availability of Data and Material, Code Availability","group":{"name":"EthicsHeading","label":"Declarations"}}]}}